Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population

AIMS: This study is aimed at investigating the eligibility in a real-world heart failure population for the DAPA-HF (testing dapagliflozin) and EMPEROR-reduced (testing empagliflozin) trials, comparing the eligible real-world patients to trial participants and to characterize the noneligible patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Håkansson, Erik, Norberg, Helena, Själander, Sara, Lindmark, Krister
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720587/
https://www.ncbi.nlm.nih.gov/pubmed/35024052
http://dx.doi.org/10.1155/2021/1894155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720587/
https://www.ncbi.nlm.nih.gov/pubmed/35024052
http://dx.doi.org/10.1155/2021/1894155

Ejemplares similares